Riskpilot← Back to searchSign inGet full accessNORGENOTECH AS
ASActiveOrg 897365812Ullernchausséen 64, 0379 OsloResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20115 employeeswww.norgenotech.no
Revenue 2024
NOK 722K
-78% vs 2023
EBITDA margin
-33.9%
-136% vs 2023
Equity ratio
36.0%
Financial strength
Net profit 2024
NOK -208K
-144% vs 2023
| Revenue | NOK 722K | -78% |
| EBITDA | NOK -245K | -136% |
| Net profit | NOK -208K | -144% |
| Total assets | NOK 811K | -36% |
| Equity | NOK 292K | -42% |
| Employees | 5 | — |
Legal name
NORGENOTECH AS
Org number
897365812
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
21. september 2011
Share capital
NOK 127 000
Employees
5 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Sergey shaposhnikov
Company purpose
Utvikle og kommersialisere innovative metoder innen bioteknologi, samt annet som står i forbindelse med dette. Videre er formålet å investere i selskap som driver innen samme næring. Slike investeringer skal godkjennes av selskapets generalforsamling med 2/3 (to-tredjedelers) flertall.
Address
Ullernchausséen 64, 0379 Oslo
Email
info@norgenotech.no
Website
www.norgenotech.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 2 076 | 3 760 | 3 538 | 3 267 | 722 |
| Staff expenses | −1 425 | −2 625 | −2 725 | −1 605 | −422 |
| EBITDA | 103 | 95 | −246 | 680 | −245 |
| Depreciation & amort. | −47 | −46 | −47 | −15 | −4 |
| EBIT | 56 | 49 | −293 | 665 | −248 |
| Net financials | 148 | −28 | −21 | −56 | −10 |
| Profit before tax | 205 | 21 | −314 | 609 | −258 |
| Tax | 23 | 4 | −67 | 136 | −50 |
| Net profit | 182 | 18 | −247 | 474 | −208 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 279 | 1 934 | 1 271 | 1 263 | 811 |
| Equity | 256 | 273 | 27 | 500 | 292 |
| Long-term debt | 965 | 0 | 0 | 0 | 0 |
| Short-term debt | 1 058 | 1 661 | 1 245 | 763 | 519 |
| Total debt | 2 023 | 1 661 | 1 245 | 763 | 519 |
EBITDA margin
-33.9%
This company
15.8%
Market median
-315% vs market
20202024
Equity ratio
36.0%
This company
38.2%
Market median
+6% vs market
20202024
Return on equity
-71.3%
This company
18.4%
Market median
-488% vs market
20202024
Net profit margin
-28.9%
This company
8.1%
Market median
-457% vs market
20202024
Asset turnover
0.89×
This company
1.12×
Market median
+21% vs market
20202024
Debt / equity
1.78×
This company
0.62×
Market median
-187% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2011 | |
| Board of Directors | 2011 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 25.39% | 25.39% | 2022 | |
| Individual | 10.43% | 10.43% | 2024 | |
| Individual | 7.09% | 7.09% | 2024 | |
| Individual | 4.13% | 4.13% | 2024 | |
| Individual | 3.35% | 3.35% | 2024 | |
| Individual | 3.35% | 3.35% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
NORGENOTECH AS 
COMET BIOTECH ASBoard members of NORGENOTECH AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Andrew Richard Sherman Collins | Board of Directors | 0 companies |
| Gunnar Christian Brøvig | Board of Directors | 0 companies |